These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16285605)

  • 1. A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin.
    Shiina Y; Homma Y; Oguma T; Fusegawa Y; Ozawa H; Handa S; Tanabe T
    Tokai J Exp Clin Med; 2005 Sep; 30(3):149-55. PubMed ID: 16285605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H
    Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apheresis technology for prevention and regression of atherosclerosis.
    Yamamoto A; Harada-Shiba M; Kawaguchi A; Tsushima M
    Ther Apher; 2001 Aug; 5(4):221-5. PubMed ID: 11724504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis.
    Otto C; Geiss HC; Donner MG; Parhofer KG; Schwandt P
    Ther Apher; 2000 Jun; 4(3):244-8. PubMed ID: 10910028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
    Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
    Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
    Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
    Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
    Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
    Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
    Marais AD; Naoumova RP; Firth JC; Penny C; Neuwirth CK; Thompson GR
    J Lipid Res; 1997 Oct; 38(10):2071-8. PubMed ID: 9374129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severe hypercholesterolemia by LDL-apheresis: cholesterol-lowering effect and clinical evaluation.
    Saito Y; Shinomiya M; Shirai K; Yoshida S
    Beitr Infusionsther; 1988; 23():160-71. PubMed ID: 2484772
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
    Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different treatment regimens in a case of homozygous familial hypercholesterolemia.
    Palcoux JB; Meyer M; Jouanel P; Vanlieferinghen P; Malpuech G
    Ther Apher; 2002 Apr; 6(2):136-9. PubMed ID: 11982954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.
    van Tits LJ; van Himbergen TM; Lemmers HL; de Graaf J; Stalenhoef AF
    Atherosclerosis; 2006 Apr; 185(2):307-12. PubMed ID: 16005883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
    van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
    J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia.
    Schmaldienst S; Banyai S; Stulnig TM; Heinz G; Jansen M; Hörl WH; Derfler K
    Atherosclerosis; 2000 Aug; 151(2):493-9. PubMed ID: 10924726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term (14 years) effect of LDL apheresis on obstructive changes in aortocoronary saphenous-vein bypass grafts in a case of heterozygous familial hypercholesterolemia with the LDL receptor proline664 to leucine mutation.
    Takahashi K; Kobayashi J; Bujo H; Takahashi M; Taira K; Kaneko K; Tashiro J; Shinomiya M; Miyazaki A; Saito Y
    Intern Med; 2000 Oct; 39(10):804-9. PubMed ID: 11030204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy.
    Masaki N; Tatami R; Kumamoto T; Izawa A; Shimada Y; Takamatsu T; Katsushika S; Ishise S; Maruyama Y; Yoshimoto N
    Int Heart J; 2005 Sep; 46(5):833-43. PubMed ID: 16272774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Endo M; Kusakabe N; Tanioka T; Kato H; Shoji T
    Atherosclerosis; 2006 May; 186(1):126-31. PubMed ID: 16043185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked aortic valve stenosis progression after receiving long-term aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia.
    Tsuchida M; Kawashiri MA; Tada H; Takata M; Nohara A; Ino H; Inazu A; Kobayashi J; Koizumi J; Mabuchi H; Yamagishi M
    Circ J; 2009 May; 73(5):963-6. PubMed ID: 19088396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
    N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.